## Ann E Stapleton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7243499/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survey of lower urinary tract symptoms in United States women using the new lower urinary tract dysfunction research Networkâ€5ymptom Index 29 (LURNâ€SIâ€29) and a national research registry. Neurourology and Urodynamics, 2022, 41, 650-661.	1.5	5
2	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. Journal of Global Antimicrobial Resistance, 2022, 28, 18-29.	2.2	18
3	Asymptomatic Bacteriuria and Pyuria in Premenopausal Women. Clinical Infectious Diseases, 2021, 72, 1332-1338.	5.8	14
4	School Toileting Environment, Bullying, and Lower Urinary Tract Symptoms in a Population of Adolescent and Young Adult Girls: Preventing Lower Urinary Tract Symptoms Consortium Analysis of Avon Longitudinal Study of Parents and Children. Urology, 2021, 151, 86-93.	1.0	10
5	Non-invasive bladder function measures in healthy, asymptomatic female children and adolescents: a systematic review and meta-analysis. Journal of Pediatric Urology, 2021, 17, 452-462.	1.1	1
6	Normative noninvasive bladder function measurements in healthy women: A systematic review and metaâ€analysis. Neurourology and Urodynamics, 2020, 39, 507-522.	1.5	15
7	Development of Conceptual Models to Guide Public Health Research, Practice, and Policy: Synthesizing Traditional and Contemporary Paradigms. Health Promotion Practice, 2020, 21, 510-524.	1.6	19
8	Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	44
9	Revisiting the Spectrum of Bladder Health: Relationships Between Lower Urinary Tract Symptoms and Multiple Measures of Well-Being. Journal of Women's Health, 2020, 29, 1077-1090.	3.3	4
10	A Bayesian multivariate metaâ€analysis of prevalence data. Statistics in Medicine, 2020, 39, 3105-3119.	1.6	4
11	Converging on Bladder Health through Design Thinking: From an Ecology of Influence to a Focused Set of Research Questions. International Journal of Environmental Research and Public Health, 2020, 17, 4340.	2.6	5
12	Applying concepts of life course theory and life course epidemiology to the study of bladder health and lower urinary tract symptoms among girls and women. Neurourology and Urodynamics, 2020, 39, 1185-1202.	1.5	13
13	Terminology for bladder health research in women and girls: Prevention of Lower Urinary Tract Symptoms transdisciplinary consortium definitions. Neurourology and Urodynamics, 2019, 38, 1339-1352.	1.5	22
14	1484. Prevalence of Pyuria With and Without Bacteriuria in Healthy Pre-Menopausal Women. Open Forum Infectious Diseases, 2019, 6, S541-S541.	0.9	1
15	Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. Journal of Urology, 2019, 202, 282-289.	0.4	248
16	MP11-14 NORMATIVE NON-INVASIVE BLADDER FUNCTION MEASUREMENTS IN HEALTHY WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Urology, 2019, 201, .	0.4	0
17	Editorial Comment. Journal of Urology, 2019, 202, 984-984.	0.4	0
18	126. Robust and Persistent Vaginal Colonization with LACTIN-V Vaginal Lactobacillus crispatus Probiotic in a Double-Blind, Placebo-Controlled (DBPC) Phase 2b Trial to Prevent Recurrent UTI (rUTI). Open Forum Infectious Diseases, 2018, 5, S8-S8.	0.9	1

#	Article	IF	CITATIONS
19	Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations. Journal of Urology, 2018, 200, 1174-1191.	0.4	49
20	Bacterial virulence phenotypes of <i>Escherichia coli</i> and host susceptibility determine risk for urinary tract infections. Science Translational Medicine, 2017, 9, .	12.4	139
21	Fosfomycin Trometamol Is Noninferior to Trimethoprim–Sulfamethoxazole for Acute Uncomplicated Cystitis in Women. Open Forum Infectious Diseases, 2017, 4, S543-S543.	0.9	О
22	The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). Open Forum Infectious Diseases, 2017, 4, S30-S31.	0.9	6
23	Enterobacteria secrete an inhibitor of Pseudomonas virulence during clinical bacteriuria. Journal of Clinical Investigation, 2017, 127, 4018-4030.	8.2	34
24	Urosepsis: Overview of the Diagnostic and Treatment Challenges. , 2016, , 135-157.		2
25	Integrated Pathophysiology of Pyelonephritis. , 2016, , 503-522.		0
26	Asymptomatic Bacteriuria and Bacterial Interference. , 2016, , 87-120.		0
27	Pathoadaptive Mutations in Uropathogenic Escherichia coli. , 2016, , 331-357.		Ο
28	Innate Immune Responses to Bladder Infection. , 2016, , 555-564.		0
29	UropathogenicEscherichia coli-Associated Exotoxins. , 2016, , 263-276.		0
30	Proteus mirabilisand Urinary Tract Infections. , 2016, , 383-433.		13
31	Susceptibility to Urinary Tract Infection: Benefits and Hazards of the Antibacterial Host Response. , 2016, , 523-554.		Ο
32	Host Responses to Urinary Tract Infections and Emerging Therapeutics: Sensation and Pain within the Urinary Tract. , 2016, , 565-588.		1
33	Cytoprotective Effect of Lactobacillus crispatus CTV-05 against Uropathogenic E. coli. Pathogens, 2016, 5, 27.	2.8	19
34	Human Metabolome-derived Cofactors Are Required for the Antibacterial Activity of Siderocalin in Urine. Journal of Biological Chemistry, 2016, 291, 25901-25910.	3.4	31
35	The Vaginal Microbiota and Urinary Tract Infection. Microbiology Spectrum, 2016, 4, .	3.0	112
36	Urine Culture in Uncomplicated UTI: Interpretation and Significance. Current Infectious Disease Reports, 2016, 18, 15.	3.0	10

#	Article	IF	CITATIONS
37	Research START: A Multimethod Study of Barriers and Accelerators of Recruiting Research Participants. Clinical and Translational Science, 2015, 8, 647-654.	3.1	20
38	Susceptibility to First-Line Antimicrobials Among Escherichia coli and Other Uropathogens Collected From Acute Uncomplicated Cystitis in Seattle, 1998–2014. Open Forum Infectious Diseases, 2015, 2, .	0.9	0
39	Human Urinary Composition Controls Antibacterial Activity of Siderocalin*. Journal of Biological Chemistry, 2015, 290, 15949-15960.	3.4	45
40	Performance of a New Rapid Immunoassay Test Kit for Point-of-Care Diagnosis of Significant Bacteriuria. Journal of Clinical Microbiology, 2015, 53, 2805-2809.	3.9	18
41	1033Rapid detection of bacteriuria with a simple immunoassay test. Open Forum Infectious Diseases, 2014, 1, S303-S303.	0.9	0
42	Lipocalin 2 Imparts Selective Pressure on Bacterial Growth in the Bladder and Is Elevated in Women with Urinary Tract Infection. Journal of Immunology, 2014, 193, 6081-6089.	0.8	54
43	Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine, 2014, 1, 46-57.	6.1	92
44	Urinary Tract Infection Pathogenesis. Infectious Disease Clinics of North America, 2014, 28, 149-159.	5.1	31
45	Re: Voided Midstream Urine Culture and Acute Cystitis in Premenopausal Women. Journal of Urology, 2014, 191, 1300-1300.	0.4	1
46	The type 1 pili regulator gene fimX and pathogenicity island PAI-X as molecular markers of uropathogenic Escherichia coli. Microbiology (United Kingdom), 2013, 159, 1606-1617.	1.8	14
47	Voided Midstream Urine Culture and Acute Cystitis in Premenopausal Women. New England Journal of Medicine, 2013, 369, 1883-1891.	27.0	210
48	Cranberry-containing products are associated with a protective effect against urinary tract infections. Evidence-Based Medicine, 2013, 18, 110-111.	0.6	5
49	Escherichia coli Isolates That Carry <i>vat</i> , <i>fyuA</i> , <i>chuA</i> , and <i>yfcV</i> Efficiently Colonize the Urinary Tract. Infection and Immunity, 2012, 80, 4115-4122.	2.2	226
50	Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis. JAMA - Journal of the American Medical Association, 2012, 307, 583-9.	7.4	57
51	Recurrent Urinary Tract Infection and Urinary Escherichia coli in Women Ingesting Cranberry Juice Daily: A Randomized Controlled Trial. Mayo Clinic Proceedings, 2012, 87, 143-150.	3.0	105
52	The siderophore yersiniabactin binds copper to protect pathogens during infection. Nature Chemical Biology, 2012, 8, 731-736.	8.0	263
53	Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection. Clinical Infectious Diseases, 2011, 52, 1212-1217.	5.8	376
54	Presence of Putative Repeat-in-Toxin Gene <i>tosA</i> in Escherichia coli Predicts Successful Colonization of the Urinary Tract. MBio, 2011, 2, e00066-11.	4.1	51

#	Article	IF	CITATIONS
55	Fimbrial Profiles Predict Virulence of Uropathogenic Escherichia coli Strains: Contribution of Ygi and Yad Fimbriae. Infection and Immunity, 2011, 79, 4753-4763.	2.2	121
56	Family History and Risk of Recurrent Cystitis and Pyelonephritis in Women. Journal of Urology, 2010, 184, 564-569.	0.4	61
57	Toll-Like Receptor Polymorphisms and Susceptibility to Urinary Tract Infections in Adult Women. PLoS ONE, 2009, 4, e5990.	2.5	170
58	Prospective Cohort Study of Microbial and Inflammatory Events Immediately Preceding <i>Escherichia coli</i> Recurrent Urinary Tract Infection in Women. Journal of Infectious Diseases, 2009, 200, 528-536.	4.0	109
59	TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14966-14971.	7.1	124
60	Urinary Tract Infections in Women With Type 1 Diabetes Mellitus: Survey of Female Participants in the Epidemiology of Diabetes Interventions and Complications Study Cohort. Journal of Urology, 2009, 181, 1129-1135.	0.4	28
61	Genetic Variation of the Human Urinary Tract Innate Immune Response and Asymptomatic Bacteriuria in Women. PLoS ONE, 2009, 4, e8300.	2.5	68
62	<i>Escherichia coli</i> DraE Adhesin-Associated Bacterial Internalization by Epithelial Cells Is Promoted Independently by Decay-Accelerating Factor and Carcinoembryonic Antigen-Related Cell Adhesion Molecule Binding and Does Not Require the DraD Invasin. Infection and Immunity, 2008, 76, 3869-3880.	2.2	42
63	Phase I Trial of a <i>Lactobacillus crispatus</i> Vaginal Suppository for Prevention of Recurrent Urinary Tract Infection in Women. Infectious Diseases in Obstetrics and Gynecology, 2007, 2007, 1-8.	1.5	69
64	A Novel TLR4-Mediated Signaling Pathway Leading to IL-6 Responses in Human Bladder Epithelial Cells. PLoS Pathogens, 2007, 3, e60.	4.7	151
65	Cranberry Products Inhibit Adherence of P-Fimbriated Escherichia Coli to Primary Cultured Bladder and Vaginal Epithelial Cells. Journal of Urology, 2007, 177, 2357-2360.	0.4	171
66	Adherence ofLactobacillus crispatusto Vaginal Epithelial Cells From Women With or Without a History of Recurrent Urinary Tract Infection. Journal of Urology, 2006, 176, 2050-2054.	0.4	28
67	Clonal analysis reveals high rate of structural mutations in fimbrial adhesins of extraintestinal pathogenic Escherichia coli. Molecular Microbiology, 2006, 59, 975-988.	2.5	76
68	Urinary tract infection in women: New pathogenic considerations. Current Infectious Disease Reports, 2006, 8, 465-472.	3.0	4
69	Risk Factors Associated with Acute Pyelonephritis in Healthy Women. Annals of Internal Medicine, 2005, 142, 20.	3.9	182
70	Amoxicillin-Clavulanate vs Ciprofloxacin for the Treatment of Uncomplicated Cystitis in Women. JAMA - Journal of the American Medical Association, 2005, 293, 949.	7.4	142
71	Novel Mechanism of P-FimbriatedEscherichia coliVirulence in Pyelonephritis. Journal of the American Society of Nephrology: JASN, 2005, 16, 3458-3460.	6.1	7
72	Urologic Complications of Diabetes. Diabetes Care, 2005, 28, 177-185.	8.6	246

5

#	Article	IF	CITATIONS
73	EDITORIAL: A NEW CANDIDATE VACCINE FOR ESCHERICHIA COLI PYELONEPHRITIS. Journal of Urology, 2004, 171, 1686-1687.	0.4	4
74	Novel approaches to prevention of urinary tract infections. Infectious Disease Clinics of North America, 2003, 17, 457-471.	5.1	31
75	Variation in Frequency of the Virulenceâ€Factor Gene inEscherichia coliClones Colonizing the Stools and Urinary Tracts of Healthy Prepubertal Girls. Journal of Infectious Diseases, 2003, 188, 1059-1064.	4.0	17
76	Analysis of Urinary Escherichia coli Isolates for Ability To Produce Shiga Toxin. Journal of Clinical Microbiology, 2002, 40, 2247-2248.	3.9	11
77	ABO and P1 Blood Group Antigen Expression andstxGenotype and Outcome of ChildhoodEscherichia coliO157:H7 Infections. Journal of Infectious Diseases, 2002, 185, 214-219.	4.0	36
78	Urinary tract infections in patients with diabetes. American Journal of Medicine, 2002, 113, 80-84.	1.5	152
79	Precise and rapid assessment ofEscherichia coli adherence to vaginal epithelial cells by flow cytometry. Cytometry, 2002, 50, 31-37.	1.8	8
80	Effects of Vaginal Intercourse with and without a Condom on Vaginal Flora and Vaginal Epithelium. Journal of Infectious Diseases, 2001, 183, 913-918.	4.0	53
81	Clonal Relationships and Extended Virulence Genotypes amongEscherichia coliIsolates from Women with a First or Recurrent Episode of Cystitis. Journal of Infectious Diseases, 2001, 183, 1508-1517.	4.0	84
82	Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. American Journal of Obstetrics and Gynecology, 2000, 183, 967-973.	1.3	170
83	Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception, 2000, 62, 107-112.	1.5	51
84	A Prospective Study of Asymptomatic Bacteriuria in Sexually Active Young Women. New England Journal of Medicine, 2000, 343, 992-997.	27.0	253
85	Risk Factors for Recurrent Urinary Tract Infection in Young Women. Journal of Infectious Diseases, 2000, 182, 1177-1182.	4.0	422
86	Influence of the Normal Menstrual Cycle on Vaginal Tissue, Discharge, and Microflora. Clinical Infectious Diseases, 2000, 30, 901-907.	5.8	247
87	Expression of virulence factors among Escherichia coli isolated from the periurethra and urine of children with neurogenic bladder on intermittent catheterization. Pediatric Infectious Disease Journal, 2000, 19, 37-41.	2.0	49
88	Perineal Anatomy and Urine-Voiding Characteristics of Young Women with and without Recurrent Urinary Tract Infections. Clinical Infectious Diseases, 1999, 29, 1600-1601.	5.8	74
89	Prevention of recurrent urinary-tract infections in women. Lancet, The, 1999, 353, 7-8.	13.7	75
90	Effect of Staphylococcus aureus Bacteria and Bacterial Toxins on Meningeal Permeability In Vitro. Regional Anesthesia and Pain Medicine, 1999, 24, 24-29.	2.3	1

#	Article	IF	CITATIONS
91	Host Factors in Susceptibility to Urinary Tract Infections. Advances in Experimental Medicine and Biology, 1999, 462, 351-358.	1.6	13
92	The P Histo-Blood Group-Related Glycosphingolipid Sialosyl Galactosyl Globoside as a Preferred Binding Receptor for Uropathogenic Escherichia coli:  Isolation and Structural Characterization from Human Kidney. Biochemistry, 1998, 37, 17420-17428.	2.5	36
93	Inverse Association of H2O2-Producing Lactobacilli and Vaginal Escherichia coli Colonization in Women with Recurrent Urinary Tract Infections. Journal of Infectious Diseases, 1998, 178, 446-450.	4.0	247
94	<i>papG</i> Alleles of <i>Escherichia coli</i> Strains Causing Firstâ€Episode or Recurrent Acute Cystitis in Adult Women. Journal of Infectious Diseases, 1998, 177, 97-101.	4.0	89
95	Escherichia coliand the Hemolytic–Uremic Syndrome. New England Journal of Medicine, 1997, 336, 515-516.	27.0	15
96	Urovirulence Determinants in <i>Escherichia coli</i> Strains Causing Prostatitis. Journal of Infectious Diseases, 1997, 176, 464-469.	4.0	87
97	Antecedent Antimicrobial Use Increases the Risk of Uncomplicated Cystitis in Young Women. Clinical Infectious Diseases, 1997, 25, 63-68.	5.8	79
98	PREVENTION OF URINARY TRACT INFECTION. Infectious Disease Clinics of North America, 1997, 11, 719-733.	5.1	109
99	Risks for Urinary Tract Infections. ACOG Clinical Review, 1997, 2, 11.	0.1	0
100	Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papC. Infection and Immunity, 1997, 65, 2153-2159.	2.2	75
101	A Prospective Study of Risk Factors for Symptomatic Urinary Tract Infection in Young Women. New England Journal of Medicine, 1996, 335, 468-474.	27.0	577
102	Hemolytic–Uremic Syndrome in a Six-Year-Old Girl after a Urinary Tract Infection with Shiga-Toxin–ProducingEscherichia coliO103:H2. New England Journal of Medicine, 1996, 335, 635-638.	27.0	108
103	Comparison of Expression of Virulence Factors by Escherichia coli Causing Cystitis and E. coli Colonizing the Periurethra of Healthy Girls. Journal of Infectious Diseases, 1995, 172, 772-777.	4.0	18
104	Effect Of Secretor Status On Vaginal And Rectal Colonization With Fimbriated Escherichia Coli In Women With And Without Recurrent Urinary Tract Infection. Journal of Infectious Diseases, 1995, 171, 717-720.	4.0	55
105	Chromosomal Restriction Fragment Length Polymorphism Analysis of Escherichia coli Strains Causing Recurrent Urinary Tract Infections in Young Women. Journal of Infectious Diseases, 1995, 172, 440-445.	4.0	188
106	Hemagglutination, Adherence, and Surface Properties of Vaginal Lactobacillus Species. Journal of Infectious Diseases, 1995, 171, 1237-1243.	4.0	79
107	Behavioral and genetic factors related to urinary tract infection. Current Opinion in Infectious Diseases, 1993, 6, 31-36.	3.1	1
108	Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status Journal of Clinical Investigation, 1992, 90, 965-972.	8.2	150

0

#	Article	IF	CITATIONS
109	Title is missing!. JAMA - Journal of the American Medical Association, 1992, 268, 54-54.	7.4	Ο
110	Urovirulence Determinants in Escherichia coli Isolates Causing First-Episode and Recurrent Cystitis in Women. Journal of Infectious Diseases, 1991, 163, 773-779.	4.0	104
111	Postcoital Antimicrobial Prophylaxis for Recurrent Urinary Tract Infection. JAMA - Journal of the American Medical Association, 1990, 264, 703.	7.4	79
112	Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. , 0, , 459-502.		9
113	Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial Infection. , 0, , 1-25.		3
114	Origin and Dissemination of Antimicrobial Resistance among Uropathogenic <i>Escherichia coli</i> . , 0, , 179-205.		1
115	Virulence and Fitness Determinants of Uropathogenic <i>Escherichia coli</i> ., 0, , 235-261.		8
116	Invasion of Host Cells and Tissues by Uropathogenic Bacteria. , 0, , 359-381.		1
117	Epidemiology and Virulence of <i>Klebsiella pneumoniae</i> ., 0, , 435-457.		7
118	Population Phylogenomics of Extraintestinal Pathogenic <i>Escherichia coli</i> ., 0, , 207-233.		1
119	The Vaginal Microbiota and Urinary Tract Infection. , 0, , 79-86.		5
120	Urinary Tract Infections in Infants and Children. , 0, , 69-77.		1
121	Clinical Presentations and Epidemiology of Urinary Tract Infections. , 0, , 27-40.		8
122	Reservoirs of Extraintestinal Pathogenic <i>Escherichia coli</i> ., 0, , 159-177.		3
123	Structure, Function, and Assembly of Adhesive Organelles by Uropathogenic Bacteria. , 0, , 277-329.		1
124	Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. , 0, , 589-646.		6
125	Diagnosis, Treatment, and Prevention of Urinary Tract Infection. , 0, , 41-68.		2

Bacterial Prostatitis: Bacterial Virulence, Clinical Outcomes, and New Directions. , 0, , 121-134.

8